AI Article Synopsis

  • Mitochondrial DNA haplogroup H is linked to a higher risk of hypertrophic cardiomyopathy (HCM), though specific SNPs associated with this risk have not been identified.
  • A study compared the distribution of H haplogroup subtypes in 55 HCM patients with two control groups from Denmark and found a higher proportion of the H3 subtype in the HCM group.
  • The distinct proportions of H subhaplogroups suggest a difference between HCM cases and controls, although the significance of these differences remains unclear without further functional studies.

Article Abstract

Mitochondrial DNA (mtDNA) haplogroup (hg) H has been reported as a susceptibility factor for hypertrophic cardiomyopathy (HCM). This was established in genetic association studies, however, the SNP or SNP's that are associated with the increased risk have not been identified. Hg H is the most frequent European mtDNA hg with greater than 80 subhaplogroups (subhgs) each defined by specific SNPs. We tested the hypothesis that the distribution of H subhgs might differ between HCM patients and controls. The subhg H distribution in 55 HCM index cases was compared to that of two Danish mtDNA hg H control groups ( = 170 and = 908, respectively). In the HCM group, H and 12 different H subhgs were found. All these, except subhgs H73, were also found in both control groups. The HCM group was also characterized by a higher proportion of H3 compared to H2. In the HCM group the H3/H2 proportion was 1.7, whereas it was 0.45 and 0.54 in the control groups. This tendency was replicated in an independent group of Hg H HCM index cases ( = 39) from Queensland, Australia, where the H3/H2 ratio was 1.5. In conclusion, the H subhgs distribution differs between HCM cases and controls, but the difference is subtle, and the understanding of the pathogenic significance is hampered by the lack of functional studies on the subhgs of H.

Download full-text PDF

Source
http://dx.doi.org/10.1080/24701394.2020.1782897DOI Listing

Publication Analysis

Top Keywords

hcm cases
12
control groups
12
hcm group
12
susceptibility factor
8
factor hypertrophic
8
hypertrophic cardiomyopathy
8
hcm
8
subhgs
6
evolutionary dissection
4
mtdna
4

Similar Publications

Background: The utility of diagnostic genetic testing in cardiomyopathy has grown significantly, due to the discovery of novel genes and greater awareness among healthcare professionals. However, a substantial proportion of cases (around 50%) yield no causative genetic variants or have variants of unknown significance (VUS), limiting their use in clinical management and familial screening. The increase in data quantity and quality in reference databases, coupled with variant interpretation guidelines, allows for periodic reanalysis of VUS, potentially reducing diagnostic gaps.

View Article and Find Full Text PDF

Hypertrophic cardiomyopathy (HCM) and arrhythmogenic right ventricular cardiomyopathy (ARVC) are phenotypically distinct inherited cardiac diseases. This case report presents a woman aged 51 years with coinheritance of pathogenic/likely pathogenic variants of the β-myosin heavy chain ( p.Glu924Lys) and plakophilin 2 ( p.

View Article and Find Full Text PDF

Leveraging a Vision Transformer Model to Improve Diagnostic Accuracy of Cardiac Amyloidosis With Cardiac Magnetic Resonance.

JACC Cardiovasc Imaging

November 2024

Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA; Cardiovascular Innovations Research Center, Cleveland Clinic, Cleveland, Ohio, USA; Diagnostic Services Institute, Cleveland Clinic, Cleveland, Ohio, USA. Electronic address:

Background: Cardiac magnetic resonance (CMR) imaging is an important diagnostic tool for diagnosis of cardiac amyloidosis (CA). However, discrimination of CA from other etiologies of myocardial disease can be challenging.

Objectives: The aim of this study was to develop and rigorously validate a deep learning (DL) algorithm to aid in the discrimination of CA using cine and late gadolinium enhancement CMR imaging.

View Article and Find Full Text PDF
Article Synopsis
  • A significant number of patients with cardiomyopathy have undetermined genetic causes, prompting researchers to analyze mtDNA variants in these cases through the 100,000 genomes project.
  • The study scrutinized 1,363 genomes, identifying the pathogenic MT-TI m.4300A>G variant in four hypertrophic cardiomyopathy patients who had previously been undiagnosed, representing 0.6% of HCM cases without a known genetic cause.
  • Findings suggest that MT-TI should be included in the initial genetic testing for non-syndromic hypertrophic cardiomyopathy to aid in diagnosing patients.
View Article and Find Full Text PDF

Treatment options for hypertrophic obstructive cardiomyopathy: a patient-centric review.

Expert Rev Cardiovasc Ther

November 2024

Inherited and Rare Cardiovascular Disease Unit, Department of Translational Medical Sciences, University of Campania 'Luigi Vanvitelli', AORN dei Colli, Monaldi Hospital, Naples, Italy.

Article Synopsis
  • Hypertrophic cardiomyopathy (HCM) is a condition characterized by thickening of the heart's left ventricle walls, affecting 1 in 200-500 people, with 60% of cases being hereditary.
  • The review discusses various treatments for HCM, including medications (like beta-blockers and calcium channel blockers) and surgical options, along with the importance of personalized patient care in improving outcomes.
  • Future treatments, such as new drugs and gene therapies, are also highlighted, emphasizing the significance of tailoring management strategies to individual patient needs and preferences.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!